Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 4, 2003. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction involving the GlaxoSmithKline Employee Trust.
Material Changes
On December 3, 2003, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 10,078 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on December 4, 2003.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that two directors, Dr. J-P Garnier and Mr. J D Coombe, hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this specific text.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust prior to the December 3, 2003 transfer.
- Confirm the specific number of shares allocated to Dr. J-P Garnier and Mr. J D Coombe under the Employee Share Option Plan.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.
- Check subsequent filings for any further changes in directors' interests or trust distributions.